Is Vivus Management Delaying Its Inevitable Demise?

Vivus has had a tough time launching obesity drug Qysmia, and shares have taken a beating, losing nearly half of their value over the past year. This has caused some activist investors, led by hedge fund First Manhattan, to call for a change in leadership, including looking to replace the drugmaker's CEO and nine directors.

In this video, health-care analyst David Williamson discusses Vivus' surprise decision to push back the shareholder meeting from Monday to Thursday, First Manhattan's aggressive response, and what the outcome could mean for investors in Vivus and its obesity-drug rival.

Can Vivus pick up its lagging sales and fend off the competition, or will Arena Pharmaceuticals reign supreme in the obesity space? If you're in the dark, grab copies of The Motley Fool's premium research reports on Vivus and Arena Pharmaceuticals to stay up to date. Senior biotech analyst Brian Orelli gives investors the must-know information, including an in-depth look at the obesity market and reasons to buy and sell both stocks. Click now for an exclusive look at Arena and Vivus -- complete with a full year of free updates -- today.

The article Is Vivus Management Delaying Its Inevitable Demise? originally appeared on Fool.com.

David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.